Chemours (NYSE:CC) Price Target Lowered to $18.00 at UBS Group

Chemours (NYSE:CC) had its target price lowered by equities research analysts at UBS Group from $21.00 to $18.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the specialty chemicals company’s stock. UBS Group’s target price indicates a potential upside of 42.46% from the stock’s current price.

A number of other research firms have also issued reports on CC. Zacks Research lowered shares of Chemours from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. Weiss Ratings reissued a “sell (d)” rating on shares of Chemours in a research note on Wednesday, October 8th. Truist Financial decreased their target price on shares of Chemours from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday. Mizuho cut their price target on Chemours from $19.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, October 16th. Finally, Royal Bank Of Canada dropped their target price on Chemours from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Monday. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.50.

Chemours Price Performance

CC stock traded down $0.12 on Tuesday, reaching $12.64. The company had a trading volume of 2,179,264 shares, compared to its average volume of 3,449,698. The company’s fifty day moving average is $14.83 and its 200 day moving average is $13.24. The company has a market cap of $1.89 billion, a P/E ratio of -5.69 and a beta of 1.64. The company has a debt-to-equity ratio of 13.66, a quick ratio of 0.88 and a current ratio of 1.71. Chemours has a 1 year low of $9.13 and a 1 year high of $22.38.

Chemours (NYSE:CC) last released its quarterly earnings results on Thursday, November 6th. The specialty chemicals company reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.04). Chemours had a positive return on equity of 35.27% and a negative net margin of 5.70%.The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same period last year, the firm earned $0.40 earnings per share. The business’s revenue was down .9% compared to the same quarter last year. Chemours has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts forecast that Chemours will post 2.03 earnings per share for the current year.

Institutional Trading of Chemours

Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC grew its stake in Chemours by 60.4% in the first quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company’s stock worth $54,428,000 after purchasing an additional 1,515,520 shares in the last quarter. Scopia Capital Management LP boosted its holdings in Chemours by 71.7% in the second quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company’s stock worth $38,418,000 after purchasing an additional 1,401,539 shares during the period. Vanguard Group Inc. increased its stake in Chemours by 8.3% during the first quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company’s stock valued at $223,069,000 after purchasing an additional 1,263,047 shares during the last quarter. State Street Corp raised its holdings in shares of Chemours by 22.7% during the second quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock worth $70,009,000 after purchasing an additional 1,131,682 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Chemours by 41.4% in the 2nd quarter. Geode Capital Management LLC now owns 3,484,416 shares of the specialty chemicals company’s stock worth $39,901,000 after buying an additional 1,020,933 shares during the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.